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Anti-inflammatory impact of minocycline in a mouse  
model of tauopathy
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Alzheimer’s disease (AD) is characterized by the extracellular deposition of β-amyloid in senile 
plaques, the intraneuronal accumulation of hyperphosphorylated tau aggregates as neurofibrillary 
tangles, and progressive neuronal loss leading to the onset of dementia. Increasing evidence 
suggests that neuroinflammatory processes contribute to the progression of AD. Minocycline 
is a semi-synthetic tetracycline derivative commonly used in the treatment of acne. Many 
studies have revealed that minocycline also has potent anti-inflammatory actions that are 
neuroprotective in rodent models of Huntington’s disease, Parkinson’s disease and motor 
neuron disease. Recently, we demonstrated that minocycline reduces the development of 
abnormal tau species in the htau mouse model of Alzheimer’s disease. We have now extended 
these findings by examining the impact of minocycline on inflammatory processes in htau 
mice. Immunohistochemical analysis revealed that minocycline treatment resulted in fewer 
activated astrocytes in several cortical regions of htau mice, but did not affect astrocytosis in 
the hippocampus. We found htau mice have significantly elevated amounts of several cortical 
pro-inflammatory cytokines. In addition, we find that minocycline treatment significantly reduced 
the amounts of several inflammatory factors, including monocyte chemoattractant proteins 1 
and 5, interleukins -6 and -10, eotaxin, and I-309. Furthermore, the reduced amounts of these 
cytokines significantly correlated with the amount of tau phosphorylated at Ser396/404 in the 
cortex of htau mice. These results may reveal new cytokine targets of minocycline that could 
be associated with its inhibition of tau pathology development in vivo. It is possible that further 
investigation of the role of these cytokines in neurodegenerative processes may identify novel 
therapeutic targets for Alzheimer’s disease and related disorders.
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2009), S100β (Van Eldik and Griffin, 1994), and monocyte chem-
oattractant protein (MCP-1) (Ishizuka et al., 1997). Indeed, the 
amount of MCP-1 in brain tissue has recently been identified as 
a major predictor of AD (Sokolova et al., 2009). The severity of 
neuroinflammation is reported to correlate with the extent of brain 
atrophy (Cagnin et al., 2001) and cognitive decline (Parachikova 
et al., 2007) observed in AD patients. 
While  most  studies  have  concentrated  on  the  relationship 
between inflammation and amyloid pathology in AD, increasing 
evidence indicates that tau pathology is also associated with neu-
roinflammation. Substantial reactive astrocytosis and microgliosis 
is evident in many transgenic mice over-expressing wild-type or 
mutant human tau (reviewed in Noble et al., 2010). For example, the 
pattern of activated glia correlates closely with the distribution and 
density of NFTs in P301S transgenic mice (Yoshiyama et al., 2007). 
In addition, in transgenic mice that develop both tau and amyloid 
pathology (3 × Tg-AD line), lipopolysaccharide-induced activation 
of glia exacerbates tau, but not amyloid pathology (Kitazawa et al., 
2005). Furthermore, recent work has shown that tau is also a target 
of non-steroidal anti-inflammatory drugs, with reduced tau phos-
phorylation and memory impairment observed following treat-
ment of 3 × Tg-AD mice with ibuprofen (McKee et al., 2008). 
IntroductIon
Tauopathies  are  a  group  of  neurodegenerative  disorders  that 
account for the most common forms of dementia, and include 
Alzheimer’s  disease  (AD)  and  frontotemporal  dementia  with 
Parkinsonism linked to tau mutations on chromosome 17 (FTDP-
17T). Tauopathies are characterized by the deposition of hyper-
phosphorylated aggregates of the microtubule-associated protein 
tau in neurons and glia in the central nervous system (CNS). The 
characteristic tau pathology in these diseases results from abnormal 
processing of tau, a predominantly neuronal protein, whose main 
functions include polymerization of tubulin, stabilization of the 
microtubule cytoskeleton, and regulation of axonal transport (Buée 
et al., 2000; Gallo et al., 2007; Hanger et al., 2009a,b). 
In most tauopathies, prolonged and widespread activation of 
astrocytes and microglia is apparent in postmortem brain (Salmina, 
2009; Mandrekar-Colucci and Landreth, 2010). This characteristic 
neuroinflammation, while not necessarily causative, is increasingly 
regarded as an important modulator of disease progression. In 
AD brain, increased release of several pro-inflammatory media-
tors from activated glia has been reported. These factors include 
IL-(interleukin)-1β (Griffin et al., 1995), IL-6 (Huell et al., 1995), 
tumor necrosis factor (TNF)-α (Dickson et al., 1993), macrophage 
inflammatory protein (MIP)-1β (Xia et al., 1998), IL-18 (Ojala et al., 
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freshly prepared each day. Control htau mice received only sterile 
NaCl (vehicle) for comparison. Mice were sacrificed by cervical dislo-
cation 2 h after the final treatment. One hemisphere was immediately 
snap-frozen on dry ice for biochemical analysis, while the other was 
immersion fixed in 4% (w/v) paraformaldehyde (PFA) in PBS. 
Animals were maintained and treated in accordance with the 
Animals (Scientific Procedures) Act, 1986, following approval by 
the local ethical review committee.
ImmunohIstochemIstry
Hemibrains were fixed in 4% (v/v) PFA overnight at 4°C, washed in 
PBS and stored at 4°C in PBS containing 0.1% (w/v) sodium azide. 
Prior to sectioning, hemispheres were immersed in cryoprotectant 
solution (30% (w/v) sucrose in 50 mM tris-buffered saline [TBS]) 
for 48 h. Thick coronal sections (40-μm) were then cut on a Leitz 
1321 freezing microtome. Sections were collected in 30% (v/v) 
ethylene glycol, 15% (w/v) sucrose, 0.05% (w/v) sodium azide in 
50 mM TBS, and stored at 4°C prior to histological processing. 
A one in six series of sections was used for immunohistochemistry 
with an antibody directed against glial fibrillary acidic protein (GFAP) 
(DAKO Ltd.) according to a standard protocol (Pontikis et al., 2005). 
Briefly, endogenous peroxidase activity was quenched by incubating 
sections in 1% (v/v) H2O2 in TBS for 15 min, followed by washing. After 
blocking in 15% (v/v) normal serum for 2 h, sections were incubated 
overnight with the GFAP antibody (1/5000). A biotinylated anti-rabbit 
IgG secondary antibody (Vector Laboratories) was used in combina-
tion with an avidin–biotin peroxidase complex (Vectastain Elite ABC 
Kit, Vector Laboratories) for antigen detection. Immunoreactivity was 
visualized using a 0.05% (w/v) DAB solution, with the staining times 
carefully controlled with all batches of sections stained at the same 
time. Sections were mounted on gelatin-chrome alum coated glass 
slides prior to clearing through a graded series of alcohol.
QuantItatIve analysIs of ImmunohIstochemIcal staInIng
The intensity of GFAP labeling was quantified using a semi-auto-
mated thresholding image analysis system (Pontikis et al., 2004). 
This analysis was performed blind to treatment. Briefly, 40 non-
overlapping images were captured, on four consecutive sections, 
through distinct brain regions. All RGB images were captured via 
a live video camera (JVC, 3CCD, KY-F55B), mounted onto a Zeiss 
Axioplan microscope using a ×40 objective. Images were subse-
quently   analyzed using Image-Pro Plus 4.0 (Media Cybernetics) 
image  analysis  software.  Data  were  plotted  graphically  as  the 
mean percentage area of immunoreactivity per field ± SEM for 
each region.
cytokIne antIbody arrays
Frozen cortical tissue was homogenized in lysis buffer (50 mM 
TBS [pH 7.4], 2 mM ethylene glycol tetraacetic acid (EGTA), 
1 mM phenylmethylsulphonylfluoride (PMSF), 1 mM sodium 
orthovanadate, 1 mM sodium fluoride, and protease inhibitor cock-
tail) using a mechanical homogenizer (Polytron; Fisher Scientific 
Ltd., Loughborough, UK) at 100 mg/ml (w/v). Homogenates were 
centrifuged at 20,000 g av for 20 min at 4°C, and supernatants were 
collected. Protein concentrations were determined using a BCA 
protein assay kit (Pierce Endogen), and 10 μg protein from each 
sample was analyzed by Cytokine Array, as described below.
Minocycline is a tetracycline-derived antibiotic with proven 
  neuroinflammatory properties (Familian et al., 2006; Noble et al., 
2009b) that has been shown to slow disease onset and confer neuro-
protection in a number of mouse models of CNS diseases, including 
Parkinson’s disease (Du et al., 2001) Huntingdon’s disease (Chen 
et al., 2000; Wang et al., 2003) amyotrophic lateral sclerosis (Kriz 
et al., 2002; Zhu et al., 2002), multiple sclerosis (Popovic et al., 
2002), spinal cord injury (SCI) (Lee et al., 2003; Stirling et al., 2004; 
Teng et al., 2004), and traumatic brain injury (Sanchez Mejia et al., 
2001). Furthermore, recent work has demonstrated that minocy-
cline treatment affects behavioral impairments and plaque forma-
tion in APP transgenic mice (Seabrook et al., 2006; Cuello et al., 
2010), inhibits neuronal death and attenuates learning and memory 
deficits following administration of Aβ to rats (Ryu et al., 2006; 
Choi et al., 2007), and reduces cognitive deficits in the 3 × Tg-AD 
mouse line (Parachikova et al., 2010). Although many of the ben-
eficial effects of minocycline are attributed to its inhibitory actions 
on inflammatory and/or apoptotic cell death pathways, the precise 
targets by which minocycline protects from neuronal death have 
not yet been identified. 
In a recent study we found that administration of minocycline 
reduced the development of disease-associated tau species in the 
htau mouse model of tauopathy (Noble et al., 2009a). Htau mice 
develop age-dependent tau pathology in the hippocampus and 
cortex (Andorfer et al., 2003, 2005), with the resulting neurode-
generation preceded by deficits in object recognition and spatial 
memory (Polydoro et al., 2009). Here, we have extended these 
previous findings by examining the impact of minocycline treat-
ment on neuroinflammatory processes in htau mice. We find that 
minocycline treatment of relatively young htau mice reduces corti-
cal, but not hippocampal astrocytosis. In addition, using unbiased 
methods, we have identified several pro-inflammatory mediators 
whose cortical protein amounts are significantly elevated in htau 
mice compared to wild-type controls, and that are significantly 
altered following minocycline treatment. Furthermore, the cortical 
amounts of selected cytokines correlate strongly with the amount 
of tau phosphorylated at Ser396/404 in the cortex of htau mice. 
Thus, this work has identified novel cytokine targets of minocy-
cline that may be closely associated with the development of tau 
pathology in a mouse model of tauopathy. It is possible that iden-
tifying the role of these cytokines in tau-associated neurodegen-
eration may reveal novel therapeutic targets for AD and related 
  neurodegenerative tauopathies.
materIals and methods
anImals and treatment protocol
Tau  transgenic  mice  (htau  line)  were  obtained  from  Jackson 
Laboratories (Bar Habor, Maine, USA). Htau mice (Andorfer et al., 
2003) were originally generated by crossing 8c mice that express the 
entire wild-type human gene (Duff et al., 2000), with tau knock-out 
(KO) mice that have a targeted disruption of exon 1 of tau (Tucker 
et al., 2001). For this study 3- to 4-month-old htau mice, and wild-
type controls on an identical genetic background, were used. Htau 
mice received intraperitoneal injections of 10 mg/kg minocycline 
hydrochloride (Sigma) in phosphate buffered saline (PBS) daily for 
14 days. According to the methods of the Friedlander group (Zhu 
et al., 2002; Wang et al., 2003; Zhang et al., 2003), minocycline was www.frontiersin.org  October 2010  | Volume 1  | Article 136  |  3
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Mouse  Cytokine  Array  Panels  were  used  according  the 
  manufacturers instructions (R&D Systems, Inc.). Briefly, cortical 
lysates were mixed with a cocktail of biotinylated detection antibod-
ies prior to incubation at 4°C with the array membranes. Following 
washing, streptavidin-HRP was applied for 30 min at ambient tem-
perature. Immunoreactivity was then visualized using enhanced 
chemiluminescence  reagent  (GE  Healthcare).  Densitometric 
  analysis was then performed.
statIstIcal analysIs
Immunohistochemical data and Cytokine Arrays were analyzed using 
students unpaired t-tests (Graphpad Prism 5.0 Software). Correlation 
coefficients and significance were determined by Spearman’s Rho 
non-parametric  correlation  analysis  (SPPS  15.0  for  Windows). 
Differences were considered statistically significant when p < 0.05.
results
mInocyclIne treatment reduces cortIcal astrocytosIs In 
htau mIce
Increased inflammatory responses are characteristic of many trans-
genic mouse models of AD that develop tau pathology, with acti-
vated astrocytes and microglia often accumulating around neurons 
containing highly phosphorylated tau (Schindowski et al., 2006). 
To investigate the impact of minocycline treatment on astrocytosis 
in the CNS of htau mice, brain sections were immunolabeled using a 
primary antibody directed against GFAP. Changes in GFAP immuno-
reactivity in specific brain regions were first assessed qualitatively. In 
general, GFAP labeling revealed activated astrocytes throughout the 
hippocampus, piriform, primary motor, and somatosensory cortices 
of htau mice (Figure 1). Within neocortical regions, GFAP-positive 
astrocytes were almost exclusively present in laminae I, II, and VI. 
Qualitative assessment suggested that minocycline treatment 
resulted in reduced GFAP immunoreactivity in cortical regions, 
when compared to vehicle-treated htau controls. In contrast, there 
was no apparent difference in the intensity of hippocampal GFAP 
immunoreactivity between minocycline- and vehicle-treated htau 
mice. Higher magnification images revealed a protoplasmic appear-
ance of GFAP immunoreactive astrocytes in both young vehicle- 
and minocycline- treated htau mice, and there was some evidence of 
GFAP-positive astrocytes with hypertrophied cell bodies and thick-
ened processes in vehicle-treated mice only (Figure 1B). Indeed, in 
vehicle-treated htau mice considerable overlapping of neighboring 
astrocyte processes was observed, which is indicative of severe dif-
fuse astrogliosis as defined by Sofroniew and Vinters (2010). 
To quantitatively assess the intensity of GFAP staining in mino-
cycline- and vehicle-treated htau mice, a thresholding image analy-
sis system was used. The barrel field of the somatosensory cortex 
(S1BF) was selected for this analysis since this region is easily iden-
tified, and is representative of general cortical GFAP labeling. The 
barrel field of the somatosensory cortex refers to discrete multi-
neuronal units called “barrels” that are located in lamina IV of the 
somatosensory cortex (Rice and Van der Loos, 1977). However, 
when used for volumetric analysis, the term S1BF, applies to all 
laminae of the cortex in this region. 
Thresholding image analysis of GFAP immunoreactivity revealed 
a decrease in the intensity of GFAP labeling in the S1BF of mino-
cycline-treated htau mice, when compared to the  vehicle-treated 
Figure 1 | gFAP labeling in minocycline- and vehicle-treated htau mice. 
Representative images of (A) GFAP immunoreactive astrocytes in the 
somatosensory and primary motor cortices (SS and M1), piriform cortex (Pir), 
and hippocampus (HC) of 3- to 4-month-old vehicle- and minocycline-treated 
htau mice. Scale bars are 500 μm (B) Protoplasmic GFAP labeling in the 
somatosensory cortex. Scale bars are 40 μm. n = 3.
Figure 2 | Minocycline treatment reduces gFAP immunoreactivity in the 
somatosensory cortex of 3- to 4-month-old htau mice. Bar chart shows 
GFAP labeling as a % of total section area. Values represent mean ± SEM. n = 3.Frontiers in Psychiatry  |  Neurodegenerative Diseases    October 2010  | Volume 1  | Article 136  |  4
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mInocyclIne treatment reduces the proteIn amounts of 
several Inflammatory medIators In the cortex of htau mIce
Since immunohistochemical analysis revealed that minocycline 
treatment reduces astrocyte activation in htau mice, we were inter-
ested in the effect of this treatment on the cortical abundance of 
pro-inflammatory mediators. Astrocytes are known to release a 
variety of pro- and anti-inflammatory mediators in response to 
stimulation, including IL-1, IL-6, IL-8, IL-10, IP-10, MCP-1, TGF-β, 
TNF-α, and RANTES (Nair et al., 2008), many of which are known 
to be upregulated in AD brain (Cameron and Landreth, 2010; 
Galasko and Montine, 2010). The secretion of these cytokines from 
activated astrocytes is believed to drive specific immune responses, 
attract T cells, and enhance the migration of lymphocytes across 
the blood–brain barrier (Nair et al., 2008). 
Cytokine arrays were used to measure differences in cortical 
cytokine amounts in minocycline- and vehicle-treated htau mice. 
The results of this experiment revealed that minocycline treat-
ment resulted in significantly decreased cortical amounts of sev-
eral inflammatory mediators in the cortex of htau mice (Figure 4), 
including GM-CSF (p < 0.05), I-309 (p < 0.001), eotaxin (p < 0.001), 
IL-6 (p < 0.01), IL-10 (p < 0.01), macrophage-colony stimulating 
factor (M-CSF) (p < 0.01), MCP-1 (p < 0.01), MCP-5 (p < 0.01), 
and TREM-1 (p < 0.05). Of these cytokines, we have shown that 
the amounts of I-309, IL-10 and TREM-1 are increased in htau 
mice relative to wild-type controls. In addition, minocycline treat-
ment resulted in significantly increased cortical amounts of IL-17 
(p < 0.01) and IL-1β (p < 0.05) in htau cortex.
the amount of selected Inflammatory cytokInes correlates 
strongly wIth tau phosphorylatIon
We have previously shown that tau phosphorylation at the PHF1 
epitope, Ser396/404, is significantly reduced following minocycline 
treatment of 3- to 4-month-old htau mice (Noble et al., 2009a). To 
controls (mean 37.6% ± 12.6% vs mean 24.4% ± 1.8%, respectively, 
Figure 2). However this difference was not statistically significant, 
most likely due to the relatively large variability in GFAP immuno-
reactivity within the vehicle-treated group. However, the variation 
within sample groups was significantly reduced by minocycline 
treatment (p < 0.05), which likely indicates a stabilizing effect of 
minocycline on astrocyte activation.
htau mIce have elevated amounts of several cortIcal 
pro-Inflammatory cytokInes
We next examined cortical lysates from htau and wild-type mice 
to  determine  if  htau  mice  display  increased  neuroinflamma-
tory responses in comparison to wild-type controls. To achieve 
this, cytokine antibody arrays were used to assess the amount of 
cytokines present in cortical lysates from these mice. These arrays 
were selected since they allow unbiased and simultaneous meas-
urement of the amounts of 40 mouse cytokines and chemokines. 
Positive controls within each array enable standardization between 
individual membranes allowing comparisons to be made between 
different samples in independent experiments. Many of the pro-
inflammatory factors included in these arrays have been implicated 
in neuroinflammatory responses. 
The  results  of  this  work  indicated  that  htau  mice  have 
increased cortical amounts of several cytokines when compared 
to wild-type controls. In particular htau mice displayed increased 
amounts of complement (C)5a, granulocyte-colony stimulating 
factor (G-CSF), I-309, soluble inter-cellular adhesion molecule 
(sICAM)-1, interferon (IFN)-γ, interleukin (IL)-1β, IL-1ra, IL-2, 
IL-4, IL-7, IL-10, IL-12, IL-13, IL-16, Il1-7, IL-23, IL-27, monokine 
induced by IFN-γ (MIG), MIP-1α, MIP-1β, MIP-2, stromal cell-
derived factor (SDF)-1, TNFα and triggering receptor expressed 
on myeloid cells (TREM)-1, relative to wild-type controls (p < 0.05 
for all, Figure 3).
Figure 3 | Cytokine amounts in the cortex of htau and wild-type mice. Bar chart shows cytokine protein amounts in arbitrary densitometry units. Values 
represent mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001. n = 3.www.frontiersin.org  October 2010  | Volume 1  | Article 136  |  5
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have concentrated on transgenic models of AD with plaque, but not 
tangle, pathology and as a result there is limited literature relating 
to the inflammatory profile of tau transgenic mice. However, in 
mice over-expressing P301S mutant human tau, iNOS, COX-2, and 
IL-1β positive cells have been identified in affected brain regions 
(Bellucci et al., 2004). Furthermore, increased amounts of TNFα, 
IL-12, RANTES, IL-5, IL-4, and decreased amounts of eotaxin, KC, 
MIP-1α, and IL-2, have been found in 3 × Tg-AD mice compared 
to non-transgenic mice (Parachikova et al., 2010). 
Here, we showed that htau mice have increased amounts of C5a, 
G-CSF, I-309, sICAM-1, IFN-γ, IL-1β, -2, -4, -7, -10, -12, -13, -27, 
MIG, MIP-1α, MIP-1β, MIP-2, SD)-1, TNFα, and TREM-1, rela-
tive to wild-type controls. Thus, TNF-α, IL-12, and IL-4 are upregu-
lated in both htau and 3 × Tg-AD mice, while MIP-1α and IL-2 are 
decreased in 3 × Tg-AD mice, but increased in the htau line, relative 
to their respective controls. The effect of minocycline treatment on 
cytokine levels in the cortex of young htau mice was then assessed, 
since we have previously demonstrated that minocycline significantly 
reduces the development of abnormal tau species in these mice (Noble 
et al., 2009a). A number of cytokines were found to be significantly 
decreased in response to minocycline treatment, including GM-CSF, 
M-CSF, I-309, eotaxin, MCP-1, MCP-5, IL-6, and TREM-1.
GM-CSF is a hematopoietic cytokine, produced by macrophages, 
astrocytes and neurons (McGeer et al., 1996). Together, with M-CSF, 
GM-CSF stimulates microglial proliferation in vivo (Giulian and 
Ingeman, 1988). Increased amounts of both GM-CSF (Tarkowski 
et al., 2001) and M-CSF (Laske et al., 2010) have been found in the 
CSF of AD patients compared to control cases, and interestingly, 
GM-CSF levels correlate with the abundance of tau proteins in CSF 
(Tarkowski et al., 2001). In addition, I-309 has recently been identi-
fied as a novel biomarker for AD and mild cognitive impairment 
(Hu et al., 2010), whilst the serum amounts of eotaxin are known to 
be increased in AD patients (Choi et al., 2008). Furthermore, CNS 
amounts of the predominantly astrocyte-derived cytokine MCP-1, 
are considered a major predictor of AD (Sokolova et al., 2009), and 
extend these findings, we next correlated the amounts of cytokines 
measured in the cortex of these animals, with amounts of pSer396/404 
tau (Table 1). We found that there were significant positive correla-
tions between the amount of tau phosphorylated at Ser396/404 and 
GM-CSF, I-309, eotaxin, IL-6, IL-10, M-CSF, MCP-1, MCP-5, and 
TREM-1. In addition, there was a significant negative correlation 
between tau phosphorylation at the PHF1 site and IL-1β, IL-17, and 
MIP-1β, cytokines we found to be increased by minocycline treatment. 
Finally, there was a significant correlation between MIG amounts and 
tau phosphorylation at Ser396/404, although the amounts of this 
cytokine were not significantly affected by minocycline treatment.
dIscussIon
Here, we have shown that htau mice have an increased inflam-
matory response, and also that minocycline treatment inhibits a 
subset of the cytokines upregulated in this transgenic mouse model 
of tauopathy. In minocycline-treated mice there was an appreci-
able decrease in astrocytosis in all cortical regions, but no effect 
on the intensity of GFAP labeling in the hippocampus. The rea-
son for a lack of an effect of minocycline on astrocytosis within 
the hippocampus is not understood, but may reflect the relatively 
high level of GFAP expression evident in this brain region, even in 
neurologically normal control mice. In general, there was abundant 
labeling of activated astrocytes in the neocortex, piriform cortex 
and hippocampus of htau mice. It has been shown previously in tau 
transgenic mice that glial activation accompanies the development 
of tau pathology (Bellucci et al., 2004; Yoshiyama et al., 2007). This 
might suggest that astrocyte activation precedes the development 
of tau pathology in htau mice, and indeed this has been suggested 
in other mouse models of tauopathy (Schindowski et al., 2006).
Astrocytes are known to release a variety of factors when acti-
vated in vitro and in vivo, including complement factors, iNOS, 
COX-2, and various interleukins (Akiyama et al., 2000a,b). A recent 
review summarizes inflammatory responses in various transgenic 
mouse models of AD (Schwab et al., 2009). Most studies so far 
Figure 4 | The effect of minocycline treatment on protein amounts of inflammatory mediators in the cortex of 3- to 4-month-old htau mice. Bar chart 
shows the protein amounts of cytokines in the cortex of minocycline-treated as a percentage of those in vehicle-treated htau mice. Values represent mean ± SEM, 
*p < 0.05, **p < 0.01, *** p < 0.001. n = 4.Frontiers in Psychiatry  |  Neurodegenerative Diseases    October 2010  | Volume 1  | Article 136  |  6
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IL-6 co-localizes with plaque-associated microglia (Bauer et al., 1991; 
Huell et al., 1995). To date, there is no known link between MCP-5 
or TREM-1 and AD or related tauopathies. 
Minocycline treatment of htau mice also significantly increased 
the cortical amounts of two inflammatory mediators, IL-17 and Il-1β. 
IL-17 functions in a synergistic manner to IL-6, and IL-17 protein 
amounts are reported to be increased in the brains of transgenic 
AD mice (Jin et al., 2008). IL-1β co-localizes with amyloid plaques 
in AD brain, and minocycline treatment has previously been shown 
to suppress secretion of IL-1β from Aβ-treated microglia in culture 
(Seabrook et al., 2006). The reason for the apparent discrepancy in the 
effect of minocycline treatment on IL-1β in amyloid and tau models 
of AD is not clear, but is worthy of further investigation. 
Indeed, a recent paper by Parachikova using the 3 × Tg-AD 
model has raised several discrepancies between our findings, and 
those that they have reported. While, we detected reduced tau phos-
phorylation at Ser202 and Ser396/404 in htau mice treated with 
minocycline (Noble et al., 2009a), in 3 × Tg-AD mice, minocycline 
treatment did not affect tau phosphorylation at Ser199/202, reduced 
phosphorylation at Thr212/Ser214, and increased tau phosphoryla-
tion at Ser396/400/403/404 (Parachikova et al., 2010). Furthermore, 
while both Parachikova et al. (2010) and ourselves both found 
reductions in GFAP in minocycline-treated mice, these authors 
detected decreased amounts of TNFα and RANTES, two cytokines 
not affected here. Furthermore, here we show a significant decrease 
in eotaxin amounts, while Parachikova et al. (2010) report that this 
cytokine is increased by minocycline treatment of 3 × Tg-AD mice. 
There are differences in the administration method utilized by these 
studies (chow vs intraperitoneal injection), the method used to 
detect cytokine amounts (Bio-plex multiplex analysis vs Antibody 
cytokine arrays) and in the antibodies used to examine tau phos-
phorylation, thus the reasons for these discrepancies are not clear. 
However, it is likely that the distinct findings of these studies may 
likely be related to the elevated Aβ present in the 3 × Tg-AD line, 
which may induce distinct inflammatory responses and intracel-
lular signaling pathways to those present in the htau mouse line. In 
support of this, recent work from Mastrangelo et al. (2009) report 
that administration of IFN-γ to 3 × Tg-AD mice results in an attenu-
ation of tau phosphorylation, but increased Aβ pathology. Thus, 
it is possible that individual pro-inflammatory cytokines may be 
(i) differentially regulated by Aβ and tau, and (ii) exert opposing 
effects on these two important proteins. 
In summary, we have demonstrated that minocycline treatment of 
htau mice reduces the activation of cortical astrocytes, and lowers the 
cortex amounts of several pro-inflammatory mediators implicated 
in AD. The results of this work have identified novel CNS cytokine 
targets of minocycline, including GM-CSF, M-CSF, I-309, MCP-5, 
and TREM-1. We have previously shown that minocycline treatment 
reduced the amount of aggregated tau in the cortex of young htau 
mice (Noble et al., 2009a), and it is possible that the data presented 
here may suggest that several, previously unreported cytokines, could 
be associated with the development of tau pathology.
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Table 1 | Correlation between cortical amounts of pSer396/404 tau and 
cytokines.
Cytokine  r2  p
BLC  0.095  ns
C5α  0.119  ns
G-CSF  0.238  ns
gM-CSF  0.810  *
i-309  0.905  *
eotaxin  0.952  ***
sICAM  0.714  ns
IFN-γ  0.238  ns
IL-1α  −0.643  ns
IL-1β  −0.833  *
IL-1ra  0.167  ns
IL-2  0.548  ns
IL-3  0.143  ns
IL-4  0.480  ns
IL-5  0.262  ns
iL-6  0.786  *
IL-7  −0.190  ns
iL-10  0.833  *
IL-13  0.571  ns
IL-12 p70  0.476  ns
IL-16  −0.710  ns
IL-17  −0.952  ***
IL-23  0.119  ns
IL-27  0.429  ns
IP-10  0.619  ns
iTAC  0.595  ns
KC  0.524  ns
MCSF  0.762  *
MCP-1  0.833  *
MCP-5  0.851  *
MIG  0.929  **
MIP-1α  0.648  ns
MIP-1β  −0.835  *
MIP-2  −0.524  ns
RANTES  −0.381  ns
SDF-1  −0.238  ns
TARC  0.657  ns
TIMP-1  0.643  ns
TNFα  0.643  ns
TreM-1  0.905  **
Non-parametric  Spearman’s  Rho  statistical  analysis  was  used  to  assess  the 
correlation  between  the  amount  of  tau  phosphorylated  at  Ser396/404  and 
pro-  inflammatory mediator amounts in the cortex of minocycline- and vehicle-
treated htau mice. The correlation coefficient (r) and statistical significance (p) is 
shown. Cytokines significantly reduced, or increased, by minocycline treatment are 
highlighted in bold and italics, respectively. BLC, B-lymphocyte chemoattractant; 
C5α,  complement  5α;  G-CSF ,  granulocyte-colony  stimulating  factor;  GM-CSF , 
granulocyte-macrophage-colony  stimulating  factor;  sICAM,  soluble  intracellular 
adhesion  molecule;  IFN-γ,  interferon-γ;  IL,  interleukin;  iTAC,  IFN-inducible T-cell 
cheomattractant;  KC,  cytokine-induced  neutrophil  chemoattractant;  M-CSF , 
macrophage-colony stimulating factor; MCP , monocyte chomattractant protein; 
MIG, monocyte induced by IFN-γ; MIP , macrophage inflammatory protein; SDF , 
stromal cell-derived factor; TARC, thymus and activation regulated chemokine; 
TIMP , metalloprotease; TNF , tumor necrosis factor; TREM, triggering response 
expressed on myeloid cells. n = 4. *p < 0.05, **p < 0.005, ***p < 0.0005.www.frontiersin.org  October 2010  | Volume 1  | Article 136  |  7
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